News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Verastem, Inc. (VSTM) Release: Nature Immunology Paper Highlights Potential Role Of FAK Inhibition In Hematological Malignancies


2/10/2014 8:03:34 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that a publication in Nature Immunology demonstrates the scientific rationale for FAK inhibition in B cell-ALL. “Loss-of-function in the transcription factor Ikaros appears to create a differentiation block that drives the pre-B cells into an adhesive state, promotes self-renewal and primes them for malignant potential,” said Richard Van Etten, M.D., Ph.D., Professor of Medicine, UC Irvine and Director, Chao Family Comprehensive Cancer Center. “In the current study, we demonstrate that treatment with the Verastem FAK inhibitor VS-6062 targets these malignant B-cells and leads to apoptotic cell death.”

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES